Compass Therapeutics, Inc. (NASDAQ: CMPX) is a Healthcare company (Biotechnology) with a market capitalization of $109M. The Maz Rating grades it against the other companies in its sector.
Compass Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.61, Compass Therapeutics, Inc. trades at 0.8x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -49.9%, return on invested capital of -62.0% and a free cash flow yield of -56.6%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 6.79. Over the past 52 weeks the share price ranged from $0.57 to $6.88, with a beta of 0.91.
Compass Therapeutics, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 16 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.